Literature DB >> 21108881

[Mortality time trends and the incidence and mortality estimation and projection for lung cancer in China].

Ling Yang1, Liandi Li, Yude Chen, Donald Maxwell Parkin.   

Abstract

BACKGROUND: Using the most comprehensive available data on lung cancer incidence and mortality in China, the mortality time trends were described and the incidence and mortality profile in 2000 and 2005 were estimated and projected, so as to provide evidence and reference for clinic, basic research and making prevention and control strategy for lung cancer in China.
METHODS: The Joinpoint model was used to analyze the lung cancer mortality trends during 1987-1999, based on data reported to WHO from the Ministry of Health in China. Combined with the data from the second national mortality survey in 1990-1992 and the lung cancer incidence and mortality data from several cancer registries in China which involved in Cancer Incidence in Five Continents, the 8th version, using the log-linear model (based on Poisson distribution), the incidence and mortality profile for lung cancer in 2000 and 2005 in China were estimated and projected.
RESULTS: The age-standardized mortality rates increased during the study period, especially in rural areas (the expected annual percentage changes were 2.7% in men and 3.6% for women, both were statistically significant) and showed among almost all age groups (above age 15). From 2000 to 2005, there would be 0.101 million more lung cancer deaths (from 327643 in 2000 to 428936 in 2005) and 0.116 million more new incident cases (from 381487 in 2000 to 497908 in 2005).
CONCLUSIONS: Due to the double effects from both changes in the risk factors for the disease and the population growth and aging, lung cancer is becoming one of the most common and increasing malignant neoplasmin China . The prevention and control for this disease will be theemphasis for future cancer control strategy of China in which tobacco control is critically important .

Entities:  

Year:  2005        PMID: 21108881     DOI: 10.3779/j.issn.1009-3419.2005.04.05

Source DB:  PubMed          Journal:  Zhongguo Fei Ai Za Zhi        ISSN: 1009-3419


  13 in total

1.  Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.

Authors:  Jing Deng; Wei Jia Fang; Xiao Chen Zhang; Dong Ping Wu; Hong Ming Fang; Jing Chen; Jiong Qian; Hai Bo Mou; Bin Bin Chu; Nong Xu; Li Song Teng
Journal:  Med Oncol       Date:  2011-03-12       Impact factor: 3.064

2.  Relationship between tumor size and disease stage in non-small cell lung cancer.

Authors:  Fu Yang; Haiquan Chen; Jiaqing Xiang; Yawei Zhang; Jianhua Zhou; Hong Hu; Jie Zhang; Xiaoyang Luo
Journal:  BMC Cancer       Date:  2010-09-02       Impact factor: 4.430

Review 3.  Chemokines and their receptors in lung cancer progression and metastasis.

Authors:  Zeng-Hui Cheng; Yu-Xin Shi; Min Yuan; Dan Xiong; Jiang-Hua Zheng; Zhi-Yong Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2016-05       Impact factor: 3.066

4.  Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.

Authors:  Xin Wang; Jun Zhao; Lu Yang; Li Mao; Tongtong An; Hua Bai; Shuhang Wang; Xuyi Liu; Guoshuang Feng; Jie Wang
Journal:  Med Oncol       Date:  2009-06-02       Impact factor: 3.064

5.  Tumor response and clinical toxicity associated with second-line chemotherapy regimens for advanced non-squamous non-small cell lung cancer: A retrospective cohort study.

Authors:  Chengping Hu; Yan Wang; Jianhua Chen; Shengqi Wu; Xiaoling Li; Yuqin Wang; Yicheng Yang; Narayan Rajan; Manny Papadimitropoulos; Qiong Xiao; Huan Zhan; Wendong Chen
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

6.  Descriptive data on cancerous lung lesions detected by auto-fluorescence bronchoscope: A five-year study.

Authors:  Asmitananda Thakur; Lin Gao; Hui Ren; Tian Yang; Tianjun Chen; Mingwei Chen
Journal:  Ann Thorac Med       Date:  2012-01       Impact factor: 2.219

7.  [Expression and its clinical significance of SLC22A18 in non-small cell lung cancer].

Authors:  Ming Lei; Qingshu Cheng; Yachao Zhao; Tao Liu; Xuejiao Wang; Yingchun Deng; Jing Yang; Zhipei Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-01

8.  [Effects of Feiyanning on the expression of epithelial-mesenchymal factors in highly metastatic lung cancer cells 95-D].

Authors:  Xiaozhen Zhao; Zhonghua Wu; Zhenye Xu; Zhongqi Wang; Ji Wu; Wan Su
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-06

9.  [Identification of candidate genes for lung adenocarcinoma using Toppgene].

Authors:  Guiping Wang; Yun Ye; Wenling Zheng; Wenli Ma
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-04

10.  Correlation of neuroendocrine features with prognosis of non-small cell lung cancer.

Authors:  Jianguo Feng; Huaying Sheng; Chihong Zhu; Xiaoqian Qian; Danying Wan; Dan Su; Xufeng Chen; Liming Zhu
Journal:  Oncotarget       Date:  2016-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.